Showing results (11-20 of 123) with videos related to

Sort By:
Pageof 13
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|September 5, 2025
Factors Influencing an Early Career Choice of Child and Adolescent Psychiatry Among Chinese Medical Students: An Exploratory SurveyMeirong Pan, Xinxin Yue, Ni Tang, et al.
Neuropsychiatric Disease and Treatment|February 7, 2015
An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosisTianMei Si, QingRong Tan, KeRang Zhang, et al.
CNS Drugs|July 25, 2023
Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-AnalysisQian Li, Xin Li, Chong Ye, et al.
Neuropsychiatric Disease and Treatment|January 27, 2016
Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature reviewLiLi Zhang, JiTao Li, YanJie Zhao, et al.
Frontiers in Psychiatry|May 20, 2021
Assessment of the Minimum Clinically Important Difference in Symptoms and Functions of Patients With Acute Schizophrenia: A Post hoc Analysis of an Open-Label, Single-Arm Multicenter StudyTianmei Si, Chuan Shi, Ling Sun, et al.
BMC Psychiatry|January 19, 2024
Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic reviewQian Li, Xin Li, Chong Ye, et al.
General Psychiatry|January 31, 2024
Advances in functional MRI research in bipolar disorder: from the perspective of mood statesYankun Wu, Yun-Ai Su, Linlin Zhu, et al.
Neuropsychiatric Disease and Treatment|June 12, 2024
Effectiveness of Vortioxetine in Working Patients with Major Depressive Disorder in China: A Subgroup Analysis of the RELIEVE China StudyGang Wang, Tianmei Si, Andreas Rieckmann, et al.
Expert Opinion on Pharmacotherapy|November 17, 2017
Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safetyTianmei Si, Jianmin Zhuo, Ibrahim Turkoz, et al.
Neuropsychiatric Disease and Treatment|July 16, 2019
Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophreniaTianmei Si, Jianmin Zhuo, Yu Feng, et al.
Pageof 13